Christine Brezden-Masley


Associate Scientist, Li Ka Shing Knowledge Institute


Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Division Head of Hematology / Oncology at St. Michael’s Hospital in Toronto and is the Head of the Oncology Clinical Research Group there.  She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto. She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region.  She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research.  Her main area of clinical research is cardiotoxicity from cancer therapy and is the Co-Chair of the annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is active in research, education and has been instrumental in the clinical development of the cancer program at St. Michael’s Hospital.

Please note: Dr. Brezden-Masley is no longer accepting summer students for 2018.

Recent Publications

  1. Chiu, JW, Krzyzanowska, MK, Serra, S, Knox, JJ, Dhani, NC, Mackay, H et al.. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clin Colorectal Cancer. 2017; :. doi: 10.1016/j.clcc.2017.10.010. PubMed PMID:29128266 .
  2. Wilson, FR, Coombes, ME, Wylie, Q, Yurchenko, M, Brezden-Masley, C, Hutton, B et al.. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. Syst Rev. 2017;6 (1):196. doi: 10.1186/s13643-017-0588-2. PubMed PMID:29017563 PubMed Central PMC5634826.
  3. Tang, GH, Acuna, SA, Sevick, L, Yan, AT, Brezden-Masley, C. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting. Med. Oncol. 2017;34 (9):154. doi: 10.1007/s12032-017-1018-y. PubMed PMID:28779423 .
  4. Barthur, A, Brezden-Masley, C, Connelly, KA, Dhir, V, Chan, KK, Haq, R et al.. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson. 2017;19 (1):44. doi: 10.1186/s12968-017-0356-4. PubMed PMID:28395671 PubMed Central PMC5387372.
  5. Acuna, SA, Huang, JW, Scott, AL, Micic, S, Daly, C, Brezden-Masley, C et al.. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am. J. Transplant. 2017;17 (1):103-114. doi: 10.1111/ajt.13978. PubMed PMID:27575845 .
  6. Virani, SA, Dent, S, Brezden-Masley, C, Clarke, B, Davis, MK, Jassal, DS et al.. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016;32 (7):831-41. doi: 10.1016/j.cjca.2016.02.078. PubMed PMID:27343741 .
  7. Chin-Yee, NJ, Yan, AT, Kumachev, A, Ko, D, Earle, C, Tomlinson, G et al.. Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open. ;4 (1):E66-72. doi: 10.9778/cmajo.20150033. PubMed PMID:27280116 PubMed Central PMC4866921.
  8. Gong, IY, Verma, S, Yan, AT, Ko, DT, Earle, CC, Tomlinson, GA et al.. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Res. Treat. 2016;157 (3):535-44. doi: 10.1007/s10549-016-3823-y. PubMed PMID:27271767 .
  9. Broglio, KR, Quintana, M, Foster, M, Olinger, M, McGlothlin, A, Berry, SM et al.. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016;2 (6):751-60. doi: 10.1001/jamaoncol.2015.6113. PubMed PMID:26914222 .
  10. Goldhar, HA, Yan, AT, Ko, DT, Earle, CC, Tomlinson, GA, Trudeau, ME et al.. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. J. Natl. Cancer Inst. 2016;108 (1):. doi: 10.1093/jnci/djv301. PubMed PMID:26476433 .
Search PubMed

Affiliations & Other Activities

  • Head, Oncology Clinical Research Group, St. Michael’s Hospital
  • Head, Division of Hematology/Oncology, St. Michael’s Hospital
  • Oncologist, Division of Hematology/Oncology, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto
  • Co-chair, Canadian Cardiac Oncology Network (CCON)
  • Founder, COMET Clinical Trials Consortium